Browsing Tag
SENTI-202
2 posts
FDA grants RMAT designation to Senti Biosciences’ SENTI-202 after strong early AML trial results
Discover how Senti Biosciences’ SENTI-202 earned FDA RMAT designation after strong AML trial data and what it means for patients and investors.
Senti Biosciences gets FDA orphan drug status for SENTI-202 in relapsed AML treatment
Senti Biosciences earns FDA orphan drug designation for SENTI-202 in AML. Find out how this logic-gated CAR-NK therapy could reshape leukemia treatment.